BOUCHERVILLE, QC — November 18, 2025 — Leads & Copy — LSL Pharma Group Inc. (TSXV: LSL) (TSXV: LSL.DB) has finalized its acquisition of Laboratoire Du-Var Inc., a contract manufacturer of cosmetics and natural health products, according to a press release issued November 18, 2025.
The acquisition, initially announced on July 31, 2025, significantly boosts LSL Pharma’s production capacity for liquid and semi-solid products and complements its existing manufacturing infrastructure.
François Roberge, President and CEO of LSL Pharma, stated the acquisition marks a milestone in LSL Pharma’s growth, enabling the company to increase production capacity, diversify its offerings, and attract new customers.
Founded in 1947, Laboratoire Du-Var Inc. specializes in the development and manufacturing of cosmetics, natural health products, and personal care items, including pet care products. The company is recognized for its expertise and commitment to quality, holding certifications such as cGMP, Health Canada, FDA, US OTC, Dietary Supplements, NHP, and Animal Natural Health Products, as well as C-TPAT accreditation.
The total consideration for the transaction included the renewal of Du-Var’s operating line of credit, term loan, and certain liabilities, totaling a maximum of $3.2 million. For the 12-month period ending August 31, 2025, Du-Var generated adjusted EBITDA of $0.5 million on revenues of $4.4 million. As of August 31, 2025, Du-Var had total assets of $6.9 million and total liabilities of $5.1 million, including bank loans totaling $3.0 million. The company’s facilities add 30,000 square feet of production capacity, and are expected to increase the CMO segment’s revenues by more than 25%.
LSL Pharma has been working with Du-Var’s management to ensure a seamless transition, with expectations that the transaction will be accretive once fully integrated.
LSL Pharma Group Inc. specializes in the development, manufacturing, and commercialization of sterile ophthalmic pharmaceutical products, as well as cosmetic and natural health products in various dosage forms. The companies that are part of the LSL Pharma Group are Steri-Med Pharma Inc., Laboratoire LSL Inc., Virage Santé Inc., Dermolab Pharma Ltd. and Laboratoire Du-Var Inc.
LSL Pharma aims to build an integrated pharmaceutical, cosmetic, and natural health products manufacturing hub in Canada, focusing on innovation, quality, and operational flexibility. The effective date of the transaction was November 17, 2025.
Cautionary Note Regarding Forward-looking statements, the release includes a section outlining potential risks and uncertainties that could affect actual results.
Source: LSL Pharma Group Inc.
